Samsung Bioepis begins to nullify Herceptin’s patent

Samsung Bioepis has started to prepare for a launch of Herceptin(generic name: trastuzumab) biosimilar, a breast cancer treatment, in Korea. 

According to the Intellectual Property Tribunal, Samsung Bioepis filed a (defensive) confirmation trial for the scope of the patent ‘Protein Purification Method Using Ion-Exchange Chromatography’ against the patentee, Genentech, on the 9^th.

This is a tr...